Publikationen der ABCSG (peer reviewed) 2011-2015

2015

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J

Annals of Oncology 00:1-7, 2015. Epub 2015 May 1.

https://www.ncbi.nlm.nih.gov/pubmed/25935792


Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Gnant M, Pfeiler G, Dubsky P, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger G, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer C

The Lancet

https://www.ncbi.nlm.nih.gov/pubmed/26040499


Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

Sonnenblick A, Francis P A, Azim Jr. H A, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua M G, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown JFrancis P A, Azim Jr. H A, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua M G, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J

European Journal of Cancer

https://www.ncbi.nlm.nih.gov/pubmed/26074397


Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

EBCTCG, Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R

The Lancet, 2015 Oct 3;386(10001):1353–1361. Epub 2015 Jul 23.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60908-4/fulltext


Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

EBCTCG, Dowsett M, Forbes F, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R

The Lancet. 2015 Oct 3;386(10001):1341-52. Epub 2015 Jul 23.

https://www.ncbi.nlm.nih.gov/pubmed/26211827


TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients

Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I

EBioMedicine. 2015 Jun 8;2(8):823-8. eCollection 2015 Aug.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563117/


Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients

Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M.

PharmacoEconomics (2015) 33:179–190 DOI 10.1007/s40273-014-0227-x

https://www.ncbi.nlm.nih.gov/pubmed/25404424


Tailoring therapies – improving the management of early breast cancer: St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members

Annals of Oncology 2015 Aug;26(8):1533-46. Epub 2015 May 4.

https://www.ncbi.nlm.nih.gov/pubmed/25939896


The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R and Gnant MFilipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R and Gnant M

British Journal of Cancer (2015) 112, 1405–1410 | doi: 10.1038/bjc.2015.98

https://www.ncbi.nlm.nih.gov/pubmed/25867274


Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

EBCTCG, Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.

The Lancet, 2015 Oct 3;386(10001):1341-1352. Epub 2015 Jul 23.

https://www.ncbi.nlm.nih.gov/pubmed/26211827


Adjuvant Bisphosphonates in Breast Cancer Treatment

Knauer M, Thürlimann B.

Breast Care 2014;9:319–322 DOI: 10.1159/000368760

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322690/


Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS.

Bio Med Central DOI 10.1186/s12920-015-0129-6

https://www.ncbi.nlm.nih.gov/pubmed/26297356


St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion

Gnant M, Thomssen C, Harbeck N.

Breast Care 2015;10:124–130 DOI: 10.1159/000430488

https://www.karger.com/Article/Fulltext/430488


Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman R E, Jones L, Ellis I, Cuzick J

The Lancet doi 10.1016/S0140-6736(15)01129-0

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01129-0/fulltext


2014

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Filipits M, Nielsen T, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer C, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens J, Gnant M, for the Austrian Breast and Colorectal Cancer Study Group

Clinical Cancer Research

https://www.ncbi.nlm.nih.gov/pubmed/24520097


Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, van Laethem J, Thaler J, Bridgewater J, Norgard Peterson L, Blons H, Collette L, van Cutsen E, Rougier P, Salazar R, Bedenne L, Emile J, Laurent-Puig P, Lepage C

The Lancet Oncology

https://www.ncbi.nlm.nih.gov/pubmed/24928083


Preoperative Treatment with Capecitabine, Cetuximab and Radiotherapy for Primary Locally Advenced Rectal Cancer – A Phase II Clinical Trial

Eisterer W, De Vries A, Öfner D, Rabl H, Koplmüller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F, Höfler G, Gnant M, Thaler J

Anticancer Research – International Journal of Cancer Research and Treatment

https://www.ncbi.nlm.nih.gov/pubmed/25368289


Role of bisphosphonates in postmenopausal women with breast cancer

Gnant M

Cancer Treatment Reviews

https://www.ncbi.nlm.nih.gov/pubmed/23906846


Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R

Annals of Oncology 2015 Feb;26(2):313-20. Epub 2014 Nov 17.

https://www.ncbi.nlm.nih.gov/pubmed/25403582


Prediction of Late Distant Recurrence After 5 Years of Endocriner Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M

Journal of Clinical Oncology 2015 March 10;33(8):916-922. Epub 2014 Oct 20.

https://www.ncbi.nlm.nih.gov/pubmed/25332252

2013

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Goetz MP, Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN

Clinical Cancer Research

https://www.ncbi.nlm.nih.gov/pubmed/23213055


Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger G, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M

British Journal of Cancer

https://www.ncbi.nlm.nih.gov/pubmed/23511562


Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer

Rugani P, Luschin G, Jakse N, Kirnbauer B, Lang U, Acham S

Clinical Oral Investigations

https://www.ncbi.nlm.nih.gov/pubmed/23749244


Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer

Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M, Dubsky P

British Journal of Cancer

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777005/


The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial

Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R on behalf of the Austrian Breast and Colorectal Cancer Study Group

British Journal of Cancer

https://www.ncbi.nlm.nih.gov/pubmed/23868011


Preparing for Prospective Clinical Trials: A National Initiative of an Excellence Registry for Consecutive Pancreatic Cancer Resections

Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, Schindl M, Längle F, Öfner D, Mischinger H-J, Pratschke J, Gnant M, Függer R

World Journal of Surgery

https://www.ncbi.nlm.nih.gov/pubmed/24121365


The EndoPredict score provides prognostic information on late distant metastases in ERþ/HER2 breast cancer patients

Dubsky P, Brase J C, Jakesz R, Rudas M, Singer C F, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann M C, Petry C, Weber K E, Fisch K, Kronenwett R, Gnant M, Filipits M on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

British Journal of Cancer

https://www.ncbi.nlm.nih.gov/pubmed/24157828


Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M and Dandachi N

Modern Pathology

https://www.ncbi.nlm.nih.gov/pubmed/24309322


Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

Steger G, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann B, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer A, Singer C, Muss C, Jakesz R, Gampenrieder S, Zielinski C, Fesl C, Gnant M on behalf of the Austrian Breast and Colorectal Study Group (ABCSG)

Annals of Oncology

https://www.ncbi.nlm.nih.gov/pubmed/24347519


Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlinertisch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens J, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T, on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Annals of Oncology

https://www.ncbi.nlm.nih.gov/pubmed/24347518

2012

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer

Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski C, Steger G

European Journal of Cancer

https://www.ncbi.nlm.nih.gov/pubmed/22459763


EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C F, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann M C, Petry C, Weber K E, Kronenwett R, Brase J C, Gnant M

Annals of Oncology

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574544/


Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group

Dubsky P, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer C, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger G, Greil R, Filipcic L, Gnant M

Journal of Clinical Oncology

https://www.ncbi.nlm.nih.gov/pubmed/22271481


Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients

Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky F, Riedl O, Jakesz R, Gnant M

Annals of Surgical Oncology

https://www.ncbi.nlm.nih.gov/pubmed/21743980


The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis

Hadji P, Coleman R, Gnant M, Green J

Annals of Oncology Advance Access

https://www.ncbi.nlm.nih.gov/pubmed/22730099


Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer

Knauer M, Gnant M, Fitzal F

Breast Care

https://www.ncbi.nlm.nih.gov/pubmed/22553475


Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – a two stage phase II clinical trial

Resch G, de Vries A, Öfner D, Eisterer W, Rabl H, Jagoditsch M, Gnant M, Thaler J

Radiotherapy and Oncology

https://www.ncbi.nlm.nih.gov/pubmed/21741716


Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer

Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, Jesch B, Heinzl H, Birner P

Breast Cancer Research and Treatment

https://www.ncbi.nlm.nih.gov/pubmed/22350732


Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Tausch C, Taucher S, Dubsky P, Seifer M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M

Annals of Surgical Oncology

https://www.ncbi.nlm.nih.gov/pubmed/22207051


Response to: Dual inhibition of HER2 in breast cancer treatment

Gnant M, Steger G

The Lancet

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60068-3/fulltext


Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature

Gnant M, Philippe Clézardin

Cancer Treatment Reviews

https://www.ncbi.nlm.nih.gov/pubmed/21983264


2011

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Bago-Horvath Z, Rudas M, Dubsky P

American Association for Cancer Research

https://www.ncbi.nlm.nih.gov/pubmed/21998336


A new Molecular Predictor of Distant Recurrence in ER-positive, HER2-negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer Ch, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer Ch, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber K, Feder I, Hennig G, Kronenwett R, Gehrmann M, Gnant M

American Association for Cancer Research

https://www.ncbi.nlm.nih.gov/pubmed/21807638


62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Poestlberger S, Steger G, Jakesz R, Singer C, Eidtmann H, Greil R

Bone

https://www.researchgate.net/publication/


Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel Ch, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl Ch, Greil R

The Lancet Oncology

https://www.ncbi.nlm.nih.gov/pubmed/21641868


Zoledronic acid in breast cancer: latest findings and interpretations

Gnant M

Therapeutic Advances in Medical Oncology

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210470/


Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT3NxM0, low rectal cancer a phase II study

Öfner D, DeVries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J

Strahlentherapie und Onkologie

https://www.researchgate.net/publication/


Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients with Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial

Pfeiler G, Königsberg R, Fesl Ch, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger G, Seifert m, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth Ch, Gnant M

Journal of Clinical Oncology

https://ascopubs.org/doi/10.1200/JCO.2010.33.2585


Zoledronic acid for adjuvant use in patients with breast cancer

Ressler S, Mlineritsch B, Greil R

Expert review of anticancer therapy

https://www.ncbi.nlm.nih.gov/pubmed/21417849


Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14

Tausch C, Steger G, Haid A, Jakesz R, Fridrik M, Reitsamer R, Pöstlberger S, Lang A, Gnant M, Greil R

The Breast Journal

https://www.ncbi.nlm.nih.gov/pubmed/21450019


Adjuvant bisphosphonates – an option with low estrogen?

Gnant M

Nature Reviews

https://www.nature.com/articles/nrclinonc.2011.170

Publikationen der ABCSG (peer reviewed) 2006-2010